Waters (WAT) Earnings Date & Reports

Key Takeaways

• Waters reported third-quarter 2026 revenue of $1.767 billion and adjusted earnings per share (EPS) of $4.10, topping consensus estimates of $1.75 billion and $4.00.
• Adjusted EPS climbed 21% year over year, while GAAP (Generally Accepted Accounting Principles) net income declined due to acquisition-related and restructuring costs.
• Organic revenue rose 9% (10% on a constant-currency basis) to $871 million, landing at the high end of management's guidance.
• Waters raised its full-year 2026 outlook, now projecting adjusted EPS of $14.60 to $14.70 and total revenue of $6.479 billion to $6.497 billion.
• The stock traded roughly 6% higher in pre-market activity following the announcement.
• For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages dedicated to Waters Corporation.
• Investors can also explore Trending AI Robots to see automated trading strategies currently gaining traction across the market.

Earnings Context and Why It Matters

Waters Corporation's third-quarter results mark a key milestone following its February 2026 acquisition of Becton, Dickinson's Biosciences and Diagnostics Solutions business, which dramatically expanded the company's scale. The report offers investors a clearer read on how the integration is progressing, how the legacy analytical instruments business is performing, and whether the combined company can sustain margin discipline. With life science tools demand recovering, the quarter also serves as a signal for broader laboratory spending trends. A beat on both revenue and EPS, paired with raised guidance, reinforces confidence that Waters is capturing a durable growth inflection rather than a one-time acquisition boost.

Reported Results

For the fiscal quarter ended October 3, 2026, Waters reported total revenue of $1.767 billion, ahead of the roughly $1.75 billion consensus and up sharply from $799.9 million a year earlier, reflecting the acquired businesses. Organic revenue reached $871 million, up 9% as reported and 10% in constant currency, while the acquired Biosciences and Diagnostic Solutions businesses contributed approximately $896 million.

Adjusted EPS came in at $4.10, a 21% increase from $3.40 in the prior-year period and above the $4.00 consensus estimate. On a GAAP basis, however, net income fell to $81 million, or $0.82 per share, from $149 million, or $2.50 per share, a year ago, pressured by acquisition-related, restructuring, and amortization costs. Adjusted operating margin was 30.1%, down 20 basis points year over year on the larger business structure.

Management also raised its 2026 guidance. Full-year adjusted EPS is now expected to be $14.60 to $14.70 (versus a prior $14.45 to $14.65), and total revenue is projected at $6.479 billion to $6.497 billion, a $43 million increase at the midpoint. Organic constant-currency revenue growth for the year is now guided to 9.1% to 9.7%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, saving time while surfacing potentially actionable setups. Whether you are monitoring a single ticker like WAT or searching the broader market, the AI Screener offers a structured way to narrow your focus.

Market Reaction and Investor Sentiment

Investors responded favorably to the report. Waters shares closed at $449.53 ahead of the announcement and traded up roughly 6% in pre-market activity after the beat and raised guidance. The positive reaction reflects both the strength of organic growth and the credibility of management's improved full-year outlook. Notably, orders outpaced sales by about $20 million, suggesting demand momentum extends into the fourth quarter. Sentiment was also supported by a rebound in China, where Biosciences posted its first quarter of positive growth in ten quarters. Still, some caution remains around the GAAP profit decline and heavier integration spending, which tempered operating cash flow in the period.

Forward Outlook and Key Factors to Monitor

Looking ahead, Waters guided fourth-quarter 2026 revenue of $1.801 billion to $1.819 billion and adjusted EPS of $4.58 to $4.68, implying double-digit growth in both organic and acquired businesses on a days-adjusted basis. Investors will be watching whether this acceleration materializes and whether the momentum carries into 2027.

Several catalysts are worth monitoring. First, the integration of the acquired Biosciences and Diagnostics Solutions business remains central, with management expecting to deliver over $50 million in revenue synergies in 2026 and citing an earlier-than-expected $200 million in run-rate cost synergies. Second, new product launches, including the FACSDiscover A7 flow cytometer and BACTEC FXI culture system, could drive instrument growth in the coming quarters.

Broader demand signals also matter. Continued strength in China, pharmaceutical reshoring, semiconductor and data center testing, and artificial intelligence-driven lab workflows are key growth vectors. At the same time, cost trends, margin progression, and cash-flow recovery during the integration will be closely watched, particularly given the near-term decline in operating cash flow versus the prior year.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations